Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

OptEase retrievable inferior vena cava filter: initial multicenter experience.

David Rosenthal1, James L Swischuk, Sidney A Cohen

  • 1Department of Vascular Surgery, Atlanta Medical Center, Atlanta, GA, USA. docro@mindspring.com

Vascular
|November 18, 2005
PubMed
Summary

The retrievable OptEase inferior vena cava filter (IVCF) safely prevented pulmonary embolus (PE) in 40 patients. It was successfully retrieved or repositioned up to 48 days, serving as an effective bridge to anticoagulation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Explantation of durable ventricular assist device for myocardial functional recovery in children: A report from the ACTION registry.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same author

Meeting report: Expanding access to advanced cardiac therapies, including ventricular assist devices (VADs) and heart transplantation in muscular dystrophy.

Neuromuscular disorders : NMD·2026
Same author

Primary target volume delineation for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas.

The Lancet. Oncology·2025
Same author

Target volume delineation of the neck for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas.

The Lancet. Oncology·2025
Same author

Externally validated digital decision support tool for time-to-osteoradionecrosis risk-stratification using right-censored multi-institutional observational cohorts.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2025
Same author

Evaluating observer reliability and diagnostic accuracy of CT-LEFAT criteria for post-treatment head and neck lymphedema: A prospective blinded comparative analysis.

Oral oncology·2025

Area of Science:

  • Vascular Surgery
  • Interventional Radiology
  • Cardiology

Background:

  • Pulmonary embolism (PE) poses a significant risk, necessitating preventive measures.
  • Inferior vena cava filters (IVCFs) are used to prevent PE in high-risk patients.
  • Retrievable IVCFs offer a temporary solution, but optimal implantation duration and repositioning strategies require evaluation.

Purpose of the Study:

  • To describe the clinical experience with the retrievable OptEase IVCF for PE prevention.
  • To assess the safety and efficacy of OptEase IVCF insertion and retrieval.
  • To evaluate the feasibility of repositioning the OptEase IVCF to extend implantation time.

Main Methods:

  • Retrospective analysis of 40 patients undergoing OptEase IVCF insertion at two institutions.

Related Experiment Videos

  • Patients were followed for 24 hours post-retrieval, with extended follow-up as needed.
  • Included analysis of filter retrieval times, repositioning events, and adverse outcomes.

    • Main Results:

    • Successful insertion and retrieval of the OptEase IVCF in all 40 patients.
    • No symptomatic PE, IVC injury, stenosis, bleeding, filter fracture, or migration observed.
    • Retrieval occurred between 3 and 48 days; repositioning in 11 patients extended implantation time effectively.

    Conclusions:

    • The OptEase IVCF is a safe and effective device for preventing symptomatic PE.
    • The filter can be safely retrieved or repositioned up to 48 days post-implantation.
    • OptEase IVCF serves as a valuable bridge to anticoagulation and allows for extended placement through repositioning.